1. health and fitness
2. disease
3. cancer

Prostate Imaging
Clinical Compendium
®
®
Table of Contents
Introduction.....................................................................................................................................2
Studies Using Advanced MRI Imaging Techniques for the Detection and Localization
of Prostate Cancer..........................................................................................................................3
Studies Using Advanced MRI Imaging Techniques for the Staging and Treatment Planning
of Prostate Cancer.........................................................................................................................22
Studies Using Advanced MRI Imaging Techniques for Treatment Monitoring of Prostate
Cancer...........................................................................................................................................33
Supplemental Information
iCAD’s VividLook and VersaVue Enterprise Solution........................................................40
Resources.......................................................................................................................42
Glossary of Acronyms.............................................................................................43
About iCAD...................................................................................................................44
Note: Studies marked with * indicate usage of advanced image analysis/computer-aided detection technology.
The content provided in this document is for informational purposes only. iCAD has compiled this information to
assist providers in learning about some of the clinical uses of contrast-enhanced magnetic resonance imaging
and advanced image analysis techniques for prostate imaging. This is not intended to be a comprehensive guide of
all the available clinical references pertaining to MRI imaging techniques available.
© 2010 iCAD, Inc. All rights reserved. iCAD, the iCAD logo, Never Stop Looking and VividLook are registered trademarks of iCAD, Inc. and and VersaVue is a pending trademark of iCAD, Inc. Other
company, product, and service names may be trademarks or service marks of others.
DMM136 Rev. B
Introduction
The numbers are staggering: Nearly 1 in 6 men over the age of 40 years in the U.S. will be diagnosed with prostate
cancer.1 In 2010, the American Cancer Society estimates that 217,000 men in the U.S. will be diagnosed with
prostate cancer and more than 32,000 will die from it.2 Prostate cancer is the second leading cause of death for
men, following lung cancer.3 Clearly, there is cause for concern.
Imaging of the prostate has historically been
challenging for clinicians because of the complex
T1
vascularity of the organ coupled with its location deep
within the abdominal/pelvic cavity. Diagnostic tests
such as the Prostate Specific Antigent (PSA) and
digital rectal examination (DRE), which are currently
used to determine the extent and behavior of prostate
cancer are often unreliable or provide inaccurate
results. These tests have been shown to have high
false positive and false negative rates which can lead
to unnecessary biopsies and/or under-diagnosis.
Biopsies of the prostate are blind and random, and
miss nearly 20% of cancers.4 Elevated PSA levels
cause approximately 1.6 million men in the U.S. to
have needle biopsies each year. Eighty percent of
those biopsies are negative adding more than $2 billion
in healthcare costs.5
T2
DWI
iCAD VividLook
In addition, prostate cancer treatments often result in many complications including impotence and incontinence
in up to 80% of patients.6 Conventional treatments such as radical prostatectomy and radiation therapy frequently
fail or are administered unnecessarily leaving nearly 50% of patients with one or more of the aforementioned
complications.
Despite what appears to be a crisis in men’s health, there is some good news. Prostate cancer is curable if it is
detected at an early stage when it still confined to the prostate. Through the use of advanced imaging techniques
such as magnetic resonance imaging (MRI) with dynamic contrast-enhancement (DCE), physicians can more
accurately diagnose, localize, stage and treat prostate cancer. Prostate MRI provides a more thorough diagnostic
assessment and allows for improved staging of the disease. Because of these benefits, the use of these advanced
imaging technologies is becoming more widely accepted and used throughout the U.S.
This compendium of clinical abstracts is intended to provide clinical evidence of the value of DCE MRI for imaging
the prostate. The citations are provided for each abstract so that full clinical papers may be referenced if desired.
American Cancer Society (http://www.cancer.org/downloads/STT/Cancer_Facts_and_Figures_2010.pdf)
American Cancer Society (http://www.cancer.org/downloads/STT/Cancer_Facts_and_Figures_2010.pdf)
3
American Cancer Society (http://www.cancer.org/downloads/STT/Cancer_Facts_and_Figures_2010.pdf)
4
John Hopkins Professor Robert Getzenberg (www.usatoday.com/news/health/2007-04-25-prostate-cancer-tests_N.htm)
5
John Hopkins Professor Robert Getzenberg (www.usatoday.com/news/health/2007-04-25-prostate-cancer-tests_N.htm)
6
National Cancer Institute (www.cancer.gov/cancertopics/factsheet/pcos)
1
2
2
Prostate Imaging
Detection and Localization
Studies
Prostate Cancer Detection and Localization
Quantitative Dynamic MRI and Localisation of
Non-Palpable Prostate Cancer*
F. Cornud, F. Beuvon, F. Thevenin, L. Chaveinc, A. Vieillefond, A. Descazeaux, T. Flam
Purpose
To determine whether quantitative dynamic contrast-enhanced MRI improves the performance of T2W-MRI for the
localisation of non-palpable prostate cancer (PCa) and for the estimation of tumor volume.
Materials and Methods
Twenty-three patients (PSA: 8.91+/-6.2ng/m) with a non-palpable cancer underwent endorectal MRI with T2W
and dynamic contrast enhanced (DCE) imaging before radical prostatectomy. Each level of evaluation (apex, midportion, base) was divided in eight areas (24 areas per prostate and 552 areas for the 23 patients). Localisation
and volume of tumor foci greater than 0,2cc present on the radical prostatectomy specimens were retrospectively
correlated to their MR appearance on the 552 evaluated areas. The dynamic parameters included capillary
permeability (K(trans)), maximum concentration of gadolinium after 60s of perfusion ([Gd]) and wash-out (K(ep)).
Uni- and multivariate analysis were performed to determine which parameters were predictive of PCa.
Results
Mean values of K(trans), K(ep) and [Gd] were significantly higher in the 58 tumor foci greater than 0,2 cm(3) of the
PZ and the TZ (all p<0.05). Logistic regression for each zone provided a value of the area under the ROC curve
of 0.83 for the PZ and 0.81 for the TZ (0.7 and 0.75, respectively, for the T2W imaging), only significant for the PZ
(p<0.002). Sensitivity and specificity were 79% and 77% for the PZ, 62.5 and 94% for the TZ. Above 0,2 cm(3), tumor
volume on dynamic MR showed a mean difference of 51+/-100% (range: -145 to +248%).
Conclusions
Quantitative dynamic MRI is more accurate than T2W imaging for tumor localisation of non-palpable cancer
greater than 0,2 cm(3), but the difference is only significant for the PZ. Above this volume, correlation between
tumor volume measured on dynamic MRI and that on the specimen is poor.
Cornud, F., et.al. Quantitative Dynamic MRI and Localisation of Non-Palpable Prostate Cancer. Prog. Urol.: 19(6), 2009, 401-413.
4
Prostate Cancer Detection and Localization
Imaging of Organ-Confined Prostate Cancer:
Functional Ultrasound, MRI and PET/Computed
Tomography
Philippe Puech, Damien Huglo, Grégory Petyt, Laurent Lemaitre, and Arnauld Villers
Purpose of review
To review the current status of advanced imaging techniques in identification of organ-confined prostate cancer
with a focus on their impact on patient management.
Recent Findings
Transrectal ultrasound suffers from poor accuracy despite significant technical improvements. Generally
used to distinguish cancers with extraprostatic spread, MRI is now focusing on intraprostatic prostate cancer
identification. At 1.5T, the most recent high-resolution pelvic phased-array coils provide excellent imaging of the
whole gland, including this challenging anterior part. Improvements in accuracy for cancer detection and volume
estimation result from dynamic contrast-enhanced and diffusion-weighted imaging sequences. Histological
correlations showed high sensitivity/specificity for significant volume cancers. 3T MRI scanners will improve these
results. Most of the recent PET/computed tomography imaging studies use choline derivatives (11C-choline and
18
F-fluorocholine). Their results are promising but insufficient to be currently recommended in routine practice.
Summary
Considerable advances have been made in the identification of organ-confined prostate cancer with
multiparametric MRI. Only prebiopsy MRI can provide best quality of cancer assessment and allows for targeting
biopsies. It is hoped that advances in 3T MRI as well as in radiotracers for PET/computed tomography will further
improve diagnosis, treatment selection, planning and outcomes.
Puech, Philippe, et.al. Imaging of Organ-Confined Prostate Cancer: Functional Ultrasound, MRI and PET/Computed Tomography. Current
Opinion in Urology: 19, 2009, 168-176.
5
Prostate Cancer Detection and Localization
Dynamic Contrast-Enhanced Magnetic Resonance
Imaging in the Evaluation of the Prostate*
David Bonekamp, MD, PhD and Katarzyna J. Macura, MD, PhD
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a novel MR technique that allows to
interrogate pharmacokinetic processes in the tissues at a voxel level and to generate parametric maps that can
be displayed for clinical interpretation. Dynamic contrast-enhanced MRI is an important imaging technique for
the imaging of angiogenesis and vasculogenesis because it probes the microvascular networks at a microscopic
level by being sensitive to the compartmentalization of tissue into the vascular and extravascular-extracellular
space and to the diffusion of contrast molecules across the vascular endothelium and capillary boundaries.
Dynamic contrast-enhanced MRI has already been shown to improve detection and localization of prostate
cancer, to improve prediction of extracapsular extension, determination of tumor volume, and after treatment
follow-up. In this article, we outline the fundamental principles of DCE-MRI and describe the application of DCE
methods in the imaging of the prostate.
Bonecamp, David et.al. Dynamic Contrast-Enhanced Magnetic Resonance Imaging in the Evaluation of the Prostate. Topics in Magnetic
Resonance Imaging: Volume 19, Number 6, December 2008, 273-284.
6
Prostate Cancer Detection and Localization
Computerized Analysis of Prostate Lesions in the
Peripheral Zone Using Dynamic Contrast Enhanced
MRI*
Pieter C. Vos, Thomas Hambrock, Christina A. Hulsbergen - van de Kaa, Jurgen J. Fütterer, Jelle O.
Barentsz, and Henkjan J. Huisman
A novel automated computerized scheme has been developed for determining a likelihood measure of malignancy
for cancer suspicious regions in the prostate based on dynamic contrast-enhanced magnetic resonance
imaging (MRI) (DCE-MRI) images. Our database consisted of 34 consecutive patients with histologically proven
adenocarcinoma in the peripheral zone of the prostate. Both carcinoma and non-malignant tissue were annotated
in consensus on MR images by a radiologist and a researcher using whole mount step-selection histopathology
as standard of reference. The annotations were used as regions of interest (ROIs). A feature set comprising
pharmacokinetic parameters and a T1 estimate was extracted from the ROIs to train a support vector machine as
classifier. The output of the classifier was used as a measure of likelihood of malignancy. Diagnostic performance of
the scheme was evaluated using the area under the ROC curve. The diagnostic accuracy obtained for differentiating
prostate cancer from non-malignant disorders in the peripheral zone was 0.83 (0.75-0.92). This suggests that it is
feasible to develop a computer aided diagnosis system capable of characterizing prostate cancer in the peripheral
zone based on DCE-MRI.
Vos, Pieter C. et.al. Computerized analysis of prostate lesions in the peripheral zone using dynamic contrast enhanced MRI. Med. Phys.: 35,
2008, 888-899.
7
Prostate Cancer Detection and Localization
Evaluation of T2-Weighted and Dynamic ContrastEnhanced MRI in Localizing Prostate Cancer
Before Repeat Biopsy
Alexandre Ben Cheikh, Nicolas Girouin, Marc Colombel, Jean-Marie Maréchal, Albert Gelet, Alvine
Bissery, Muriel Rabilloud, Denis Lyonnet, Olivier Rouvière
We assessed the accuracy of T2-weighted (T2w) and dynamic contrast-enhanced (DCE) 1.5-T magnetic resonance
imaging (MRI) in localizing prostate cancer before transrectal ultrasound-guided biopsy. Ninety-three patients with
abnormal PSA level and negative prostate biopsy underwent T2w and DCE prostate MRI using pelvic coil before
repeat biopsy. T2w and DCE images were interpreted using visual criteria only. MR results were correlated with
repeat biopsy findings in ten prostate sectors. Repeat biopsy found prostate cancer in 23 patients (24.7%) and
44 sectors (6.6%). At per patient analysis, the sensitivity, specificity, positive and negative predictive values were
47.8%, 44.3%, 20.4% and 79.5% for T2w imaging and 82.6%, 20%, 24.4% and 93.3% for DCE imaging. When all
suspicious areas (on T2w or DCE imaging) were taken into account, a sensitivity of 82.6% and a negative predictive
value of 100% could be achieved. At per sector analysis, DCE imaging was significantly less specific (83.5% vs.
89.7%, p<0.002) than T2w imaging; it was more sensitive (52.4% vs 32.1%), but the difference was hardly significant
(p=0.09). T2w and DCE MRI using pelvic coil and visual diagnostic criteria can guide prostate repeat biopsy, with a
good sensitivity and NPV.
Cheikh, Alexandre, et.al. Evaluation of T2-Weighted and Dynamic Contrast-Enhanced MRI in Localizing Prostate Cancer Before Repeat
Biopsy. European Radiology: 19, 2009, 770-778.
8
Prostate Cancer Detection and Localization
Usefulness of Diffusion-Weighted Imaging
and Dynamic Constrast-Enhanced Magnetic
Resonance Imaging in the Diagnosis of Prostate
Transition-Zone Cancer
T. Yoshizako, A. Wada, T. Hayashi, K. Uchida, M. Sumura, N. Uchida, H. Kitagaki, M. Igawa
Background
Conventional T2-weighted (T2-WI) magnetic resonance imaging (MRI) has poor sensitivity for prostate transitionzone (TZ) cancer detection.
Purpose
To retrospectively evaluate the clinical value of diffusion-weighted MRI (DW-MRI) and dynamic contrast-enhanced
MRI (DCE-MRI) in combination with T2-WI for the diagnosis of TZ cancer.
Material and Methods
Twenty-six TZ cancers in 23 patients with at least one tumor (tumor size >10 mm) located predominantly in the
TZ were included in the study. Sixteen peripheral-zone (PZ) cancers in 12 patients with PZ cancer but without TZ
cancer (control group) were selected by step-selection pathologic maps. All patients underwent MRI and radical
prostatectomy. MRI was obtained by a 1.5T super-conducting system with a phased-array coil. Imaging sequences
were T2-WI with fat saturation (FST2-WI), DW-MRI (single-shot echoplanar image, b=0 and 1000 s/mm2, apparent
diffusion coefficient (ADC) map findings), and DCE-MRI (3D fast spoiled gradient recalled (SPGR), contrast medium
(0.2 mmol/kg), total injection time 5 s, image acquisition 30, 60 and 90 s). Sensitivity, specificity, accuracy, and
positive predictive value (PPV) for the diagnosis of TZ cancer were evaluated in four protocols: A) FST2-WI alone, B)
FST2-WI plus DW-MRI, C) FST2-WI plus DCE-MRI, D) FST2-WI plus DW-MRI plus DCE-MRI.
Results
Sensitivity, specificity, accuracy, and PPV in protocol A (FST2-WI alone) were 61.5%, 68.8%, 64.3%, and 76.2%,
respectively. FST2-WI plus DW-MRI (protocol B) improved the sensitivity, specificity, accuracy, and PPV. In FST2-WI
plus DW-MRI plus DCE-MRI (protocol D), the number of true-negative lesions increased and false-positive lesions
decreased, and the sentivity, specificity, accuracy, and PPV were 69.2%, 93.8%, 78.6%, and 94.7%, respectively.
There was a significant difference between protocols A and D (p<0.05).
Conclusion
Adding DW-MRI to FST2-WI in the diagnosis of prostate TZ cancer increased the diagnostic accuracy. The addition
of DCE-MRI may be an option to improve the specificity and PPV of diagnosing TZ cancer with FST2-WI and DW-MRI.
Yoshizako, T., et.al. Usefulness of Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced Magnetic Resonance Imaging in the
Diagnosis of Prostate Transitional-Zone Cancer. Acta Radiologica: 10, 2008, 1207-1213.
9
Prostate Cancer Detection and Localization
Prostate Cancer Screening: The Clinical Value of
Diffusion-Weighted Imaging and Dynamic MR
Imaging in Combination with T2-Weighted Imaging
Akihiro Tanimoto, MD, Jun Nakashima, MD, Hidaka Kohno, MD, Hiroshi Shinmoto, MD, and Sachio
Kuribayashi, MD
Purpose
To evaluate the clinical value of diffusion weighted imaging (DWI) and dynamic MRI in combination with T2weighted imaging (T2W) for the detection of prostate cancer.
Materials and Methods
A total of 83 patients with elevated serum prostate specific antigen (PSA) levels (4.0 ng/mL) were evaluated by
T2W, DWI, and dynamic MRI at 1.5 T prior to needle biopsy. The data from the results of the T2W alone (protocol
A), combination of T2W and DWI (protocol B), and the combination of T2W+DWI and dynamic MRI (protocol C)
were entered into a receiver operating characteristic (ROC) curve analysis, under results of systemic biopsy as the
standard of reference.
Results
Prostate cancer was pathologically detected in 44 of the 83 patients. The sensitivity, specificity, accuracy, and
the area under the ROC curve (Az) for the detection of prostate cancer were as follows: 73%, 54%, 64%, and
0.711, respectively, in protocol A; 84%, 85%, 84%, and 0.905, respectively, in protocol B; and 95%, 74%, 86%, and
0.966, respectively, in protocol C. The sensitivity, specificity, and accuracy were significantly different between the
three protocols (P 0.01).
Conclusion
In patients with elevated serum PSA levels, the combination of T2W, DWI, and dynamic MRI may be a valuable tool
for detecting prostate cancer and avoiding an unnecessary biopsy without missing prostate cancer.
Tanimoto, Akihiro, et.al. Prostate Cancer Screening: The Clinical Value of Diffusion-Weighted Imaging and Dynamic MR Imaging in Combination with T2-Weighted Imaging. Journal of Magnetic Resonance Imaging 2007; 25:146-152.
103
Prostate Cancer Detection and Localization
Dynamic Contrast-Enhanced MRI of Benign
Prostatic Hyperplasia and Prostatic Carcinoma:
Correlation with Angiogenesis
J. Ren, Y. Huan, H. Wang, Y.-J. Changa, H.-T. Zhao, Y.-L. Ge, Y. Liu, Y. Yang
Aim
To investigate the diagnostic and differential diagnostic values of dynamic contrast-enhanced magnetic resonance
imaging (DCE MRI) in prostatic diseases, and to investigate the correlation between the parameters of SIeT
curves and angiogenesis.
Materials and Methods
Twenty-one patients with proven prostatic carcinoma (Pca) and 29 patients with proven benign prostatic
hyperplasia (BPH) were examined using DCE MRI. Diagnostic characteristics for differentiation were examined
using threshold values for maximum peak time, enhancement degree, and enhancement rate. Then, the signal
intensity-time curves (SIeT curves) were analyzed, and the correlations between the parameters of SIeT curves
and the expression levels of vascular endothelial growth factor (VEGF) and microvascular density (MVD) were
investigated. All patients underwent prostatectomy. DCE MRI and histological findings were correlated.
Results
Pca showed stronger enhancement with an earlier peak time, higher enhancement, and enhancement
rate (p < 0.05). Regarding the type of SIeT curves, in the BPH group six were type A, 10 were type B, and 13 were
type C, whereas in the Pca group, 14 were type A, six were type B, and only one was type C (Chi-square test,
c2 ¼ 13.57, P < 0.005). The VEGF and MVD expression levels of Pca were higher than those of BPH. Peak time
was negatively correlated with the expression levels of VEGF and MVD, whereas the enhancement degree and
enhancement rate showed positive correlations (Pearson correlation, p < 0.05).
Conclusion
Based on T2-weighted imaging, DCE MRI curves can help to differentiate benign from malignant prostate tissue. In
the present study the type C curve was rarely seen with malignant disease, but these results need confirmation.
Rena, J., et.al. Dynamic Contrast-Enhanced MRI of Benign Prostatic Hyperplasia and Prostatic Carcinoma: Correlation With Angiogenesis.
Clinical Radiology: 63, 2008, 153-159.
11
Prostate Cancer Detection and Localization
Dynamic Contrast-Enhanced MRI of Prostate
Cancer at 3 T: A Study of Pharmacokinetic
Parameters*
Iclal Ocak, Marcelino Bernardo, Greg Metzger, Tristan Barrett, Peter Pinto, Paul S. Albert,
Peter L. Choyke
Objective
The objectives of our study were to determine whether dynamic contrast-enhanced MRI performed at 3 T and
analyzed using a pharmacokinetic model improves the diagnostic performance of MRI for the detection of prostate
cancer compared with conventional T2-weighted imaging, and to determine which pharmacokinetic parameters
are useful in diagnosing prostate cancer.
Subjects and Methods
This prospective study included 50 consecutive patients with biopsy-proven prostate cancer who underwent
imaging of the prostate on a 3-T scanner with a combination of a sensitivity-encoding (SENSE) cardiac coil and
an endorectal coil. Scans were obtained at least 5 weeks after biopsy. T2-weighted turbo spin-echo images were
obtained in three planes, and dynamic contrast-enhanced images were acquired during a single-dose bolus
injection of gadopentetate dimeglumine (0.1 mmol/kg). Sensitivity, specificity, positive predictive value (PPV),
and negative predictive value (NPV) were estimated for T2-weighted and dynamic contrast-enhanced MRI. The
following pharmacokinetic modeling parameters were determined and compared for cancer, inflammation,
and healthy peripheral zone: Ktrans (forward volume transfer constant), kep (reverse reflux rate constant between
extracellular space and plasma, ve (the fractional volume of extracellular space per unit volume of tissue), and the
area under the gadolinium concentration curve (AUGC) in the first 90 seconds after injection.
Results
Pathologically confirmed cancers in the peripheral zone of the prostate were characterized by their low signal
intensity on T2-weighted scans and by their early enhancement, early washout, or both on dynamic contrastenhanced MR images. The overall sensitivity, specificity, PPV, and NPV of T2-weighted imaging were 94%, 37%,
50% and 89%, respectively. The sensitivity, specificity, PPV, and NPV of dynamic contrast-enhanced MRI were 73%,
88%, 75%, and 75%, respectively. Ktrans, kep and AUGC were significantly higher (p<0.001) in cancer than in normal
peripheral zone. The ve parameter was not significantly associated with prostate cancer.
Conclusion
MRI of the prostate performed at 3 T using an endorectal coil produces high-quality T2-weighted images;
however, specificity for prostate cancer is improved by also performing dynamic contrast-enhanced MRI and using
pharmacokinetic parameters, particularly Ktrans and kep, for analysis. These results are comparable to published
results at 1.5 T.
Ocak, Iclal, et.al. Dynamic Contrast-Enhanced MRI of Prostate Cancer at 3 T: A Study of Pharmacokinetic Parameters. AJR: 189, October
2007, W192-W201.
12
Prostate Cancer Detection and Localization
Dynamic Contrast Enhanced MRI in Prostate
Cancer
Roberto Alonzi, Anwar R. Padhani, Clare Allen
Angiogenesis is an integral part of benign prostatic hyperplasia (BPH), is associated with prostatic intraepithelial
neoplasia (PIN) and is key to the growth and for metastasis of prostate cancer. Dynamic contrast enhanced
magnetic resonance imaging (DCE-MRI) using small molecular weight gadolinium chelates enables non-invasive
imaging characterization of tissue vascularity. Depending on the technique used, data reflecting tissue perfusion,
microvessel permeability surface area product, and extracellular leakage space can be obtained. Two dynamic
MRI techniques (T2*-weighted or susceptibility based and T1-weighted or relaxivity enhanced methods) for prostate
gland evaluations are discussed in this review with reference to biological basis of observations, data acquisition and
analysis methods, technical limitations and validation. Established clinical roles of T1-weighted imaging evaluations
will be discussed including lesion detection and localisation, for tumour staging and for the detection of suspected
tumour recurrence. Limitations include inadequate lesion characterisation particularly differentiating prostatitis
from cancer, and in distinguishing between BPH and central gland tumours.
Alonzi, Roberto, et.al. Dynamic Contrast Enhanced MRI in Prostate Cancer. European Journal of Radiology: 63, 2007, 335-350.
13
Prostate Cancer Detection and Localization
Dynamic Contrast Enhanced, Pelvic Phased
Array Magnetic Resonance Imaging of Localized
Prostate Cancer for Predicting Tumor Volume:
Correlation With Radical Prostatectomy Findings
Arnauld Villers, Philippe Peuch, Damien Mouton, Xavier Leroy, Charles Ballereau and Laurent
Lemaitre
Purpose
We assessed the value of pelvic phased array dynamic contrast enhanced magnetic resonance imaging for
predicting the intraprostatic location and volume of clinically localized prostate cancers.
Materials and Methods
Suspicious areas on prospective pre-biopsy magnetic resonance imaging in 24 patients were assigned a magnetic
resonance imaging malignancy score and located with respect to anatomical features, gland side, and transition
and peripheral zone boundaries. The largest surface area and volume were measured. These magnetic resonance
imaging findings were compared with radical prostatectomy specimen histopathology findings.
Results
Histopathology maps detected 56 separate cancer foci. The largest tumor focus was located in the peripheral
zone in 14 patients and in the transition zone in 10. T1-weighted dynamic contrast enhanced magnetic resonance
imaging identified 30 of the 39 tumor foci greater than 0.2 cc and 27 of the 30 greater than 0.5 cc. T2-weighted
sequences were suspicious in 22 of 30 foci greater than 0.2 cc that were identified by T1-weighted dynamic contrast
enhanced magnetic resonance imaging sequences. Sensitivity, specificity, and positive and negative predictive
values for cancer detection by magnetic resonance imaging were 77%, 91%, 86% and 85% for foci greater than 0.2
cc, and 90%, 88%, 77% and 95% for foci greater than 0.5 cc, respectively. Median focus volume was 1.37 cc (range
0.338 to 6.32) for foci greater than 0.2 cc detected by magnetic resonance imaging in the peripheral zone and 0.503
cc (range 0.337 to 1.345) for those not detected by magnetic resonance imaging (p<0.05). Corresponding median
values for transition zone foci were 2.54 (range 0.75 to 16.87) and 0.435 (range 0.26 to 0.58).
Conclusions
Pre-biopsy pelvic phased array dynamic contrast enhanced magnetic resonance imaging is an accurate technique
for detecting and quantifying intracapsular transition or peripheral zone tumor foci greater than 0.2 cc. It has
promising implications for cancer detection, prognosis and treatment.
Villers, Aranuld, et.al. Dynamic Contrast Enhanced, Pelvic Phased Array Magnetic Resonance Imaging of Localized Prostate Cancer for
Predicting Tumor Volume: Correlation With Radical Prostatectomy Findings. The Journal of Urology: 176, 2006, 2432-2437.
14
Prostate Cancer Detection and Localization
How Good is MRI at Detecting and Characterising
Cancer Within the Prostate?
Alexander P.S. Kirkham, Mark Emberton, Clare Allen
Objectives
As well as detecting prostate cancer, it is becoming increasingly important to estimate its location, size and grade.
We aim to summarise current data on the efficacy of magnetic resonance imaging (MRI) in this setting.
Methods
Literature review of original research correlating MRI and histologic appearances.
Results
Estimates of the sensitivity of MRI for the detection of cancer vary widely depending on method of analysis used
and the definition of significant disease. Recent estimates using T2-weighted sequences and endorectal coils vary
from 60% to 96%. Several groups have convincingly shown that dynamic contrast enhancement and spectroscopy
each improve detection and that the sensitivity of MRI is comparable to and may exceed that of transrectal biopsy.
Specificity is not yet good enough to consider the use of MRI in screening. High-grade and large tumours are
detected significantly more often with both T2 sequences and spectroscopy. Estimation of size is improved by
dynamic contrast and spectroscopy, but errors of >25% are common.
Conclusions
The sensitivity of MRI has improved to the point that it has potential in several new areas: targeting of biopsies,
monitoring of disease burden both during active surveillance and after focal therapy, and exclusion of cancer in
patients with a raised prostate-specific antigen level.
Kirkham, Alexander P.S., et.al. How Good is MRI at Detecting and Characterising Cancer within the Prostate? European Radiology: 50, 2006,
1163-1175.
15
Prostate Cancer Detection and Localization
Localization of Prostate Cancer Using 3T MRI:
Comparison of T2-Weighted and Dynamic
Contrast-Enhanced Imaging
Chan Kyo Kim, MD, Byung Kwan Park, MD and Bohyun Kim, MD
Objective
To compare dynamic contrast-enhanced imaging and T2-weighted imaging using a 3T MR unit for the localization
of prostate cancer.
Methods
Twenty consecutive patients with biopsy-proven prostate cancer underwent both T2-weighted imaging and
dynamic contrast-enhanced imaging. At T2-weighted imaging and dynamic contrast-enhanced imaging, the
presence or absence of prostate cancer confined within the prostate without extracapsular or adjacent organ
invasion was evaluated in the peripheral zones of base, mid-gland, and apex on each side. Final decisions on
prostate cancer localization were made by consensus between two radiologists. Degrees of depiction of tumor
borders were graded as poor, fair, or excellent.
Results
Prostate cancer was pathologically detected in 64 (53%) of 120 peripheral zone areas. The sensitivity, specificity,
and accuracy for prostate cancer detection was 55%, 88% and 70% for T2-weighted imaging and 73%, 77%, and
75% for dynamic contrast-enhanced imaging, respectively. Three cancer areas were detected only by T2-weighted
imaging, 15 only by dynamic contrast-enhanced imaging, and 34 by both T2-weighted imaging and dynamic
contrast-enhanced imaging. A fair or excellent degree at depicting tumor border was achieved in 67% by T2weighted imaging and in 90% by dynamic contrast-enhanced imaging (P< 0.05).
Conclusions
Dynamic contrast-enhanced imaging at 3T MRI is superior to T2-weighted imaging for the detection and depiction
of prostate cancer and thus is likely to be more useful for preoperative staging.
Kim, Chan Kyo, et.al. Localization of Prostate Cancer Using 3T MRI: Comparison of T2-Weighted and Dynamic Contrast-Enhanced Imaging.
Journal of Computer-Assisted Tomography: 30:1, Jan/Feb 2006, 7-11.
16
Prostate Cancer Detection and Localization
Wash-In Rate on the Basis of Dynamic ContrastEnhanced MRI: Usefulness for Prostate Cancer
Detection and Localization
Jeong Kon Kim, MD, Seong Sook Hong, MD, Young Jun Choi, MD, Seong Ho Park, MD, Hanjong Ahn,
MD, Choung-Soo Kim, MD and Kyoung-Sik Cho, MD
Purpose
To evaluate the usefulness of the wash-in rate based on dynamic contrast-enhanced (DCE) MRI for the detection
and localization of prostate cancer.
Materials and Methods
In 53 patients, the wash-in rate was measured in the cancer area and in three normal areas (the peripheral
zone, inner portion of the transitional zone, and outer portion of the transitional zone). On the basis of these
data, parametric imaging was generated and then its accuracy for cancer detection and location was elevated
compared to that of T2-weighted imaging without the use of an endorectal coil. For that purpose the entire
prostate was divided into 18 segments.
Results
The wash-in rate value was greater in cancer tissue (9.2/second) than in three normal tissues (3.3/second, 6.7/
second and 3.2/second, respectively; P< 0.001). The sensitivity and specificity were greater on parametric imaging
of the wash-in rate compared to T2-weighted imaging in the entire prostate (96% and 82% vs. 65% and 60%
respectively) and the periperal zone (96% and 97% vs. 75% and 53%, P<0.05). In the transitional zone, the sensitivity
was greater on parametric imaging (96%) than on T2-weighted imaging (45%, P=0.016), but the specificity was
similar (51% vs. 73%; P=0.102).
Conclusion
The wash-in rate based on DCE-MRI is a useful parameter for prostate cancer detection and localization.
Kim, Jeong Kon et.al. Wash-In Rate on the Basis of Dynamic Contrast-Enhanced MRI: Usefulness for Prostate Cancer Detection and
Localization. Journal of Magnetic Resonance Imaging: 22, 2005, 639-646.
17
Prostate Cancer Detection and Localization
Prostate Tissue Composition and MR
Measurements: Investigating the Relationships
Between ADC, T2, Ktrans, Ve and Corresponding
Histologic Features*
Deanna L. Langer, Theodorus H. van der Kwast, MD, Andrew J. Evans, MD, Anna Plotkin, MD,
John Trachtenberg, MD, Brian C. Wilson, Masoom A. Haider, MD
Purpose
To investigate relationships between magnetic resonance (MR) imaging measurements and the underlying
composition of normal and malignant prostate tissue.
Materials and Methods
Twenty-four patients (median age, 63 years; age range, 44-72 years) gave informed consent to be examined for
this research ethics boards-approved study. Before undergoing prostatectomy, patients were examined with T2weighted, diffusion-weighted, T2 mapping, and dynamic constrast material-enhanced MR imaging at 1.5T. Maps
of apparent diffusion coefficient (ADC), T2, volume transfer constant (Ktrans), and extravascular extracellular space
(Ve) were calculated. Whole-mount hematoxylin-eosin-stained sections were generated and digitized at histologic
resolution. Percentage areas of tissue components (nuclei, cytoplasm, stroma, luminal space) were measured
by using image segmentation. Corresponding regions on MR images and histologic specimens were defined by
singa anatomically defined segments in peripheral zone (PZ) and central gland tissue. Cancer and normal PZ
regions were identified at histopathologic analysis. Each MR parameter-histologic tissue component pair was
assessed by using linear mixed-effects models, and cancer versus normal PZ values were compared by using
nonparametric tests.
Results
ADC and T2 were inversely related to percentage area of nuclei and percentage area of cytoplasm and positively
related to percentage area of luminal space ( P<_ .01). These trends were reversed for Ktrans (P< .001). Ktrans had a
significantly negative (P = .01) slope versus percentage area of stroma, and Ve had a positive (P = .0008) slope versus
percentage area of stroma. The Ve was inversely proportional tp the percentage area of nuclei (P = .05). All MR
imaging parameters (P<- .05) and the percentage areas of all tissue components (P<- .001) except stroma (P > .48)
were significantly different between cancer and normal PZ tissue.
18
Prostate Cancer Detection and Localization
Prostate Tissue Composition and MR
Measurements: Investigating the Relationships
Between ADC, T2, Ktrans, Ve and Corresponding
Histologic Features*
(con’t from page 18)
Conclusion
MR imaging-derived parameters measured in the prostate were significantly related to the proportion of specific
histologic components that differ between normal and malignant PZ tissue. These relationships may help define
imaging-related histologic prognostic parameters for prostate cancers.
Langer, Deanna L., et.al. Prostate Tissue Composition and MR Measurements: Investigating the Relationships between ADC, T2, Ktrans, Ve,
and Coresponding Histologic Features. Radiology: 255:2, May 2010, 485-494.
19
Prostate Cancer Detection and Localization
Dynamic MRI and CAD vs. Choline MRS: Where is
the Detection Level for a Lesion Characterisation
in Prostate Cancer?*
Michael Schmuecking, Carsten Boltze, Hagen Geyer, Henning Salz, Bert Schilling, Thomas G.
Wendt, Karl-Heinz Kloetzer, Christiane Marx
Purpose
To evaluate the role of pre-interventional fused high resolution T2-weighted images with parametrically analysed
dynamic contrast enhanced T1-weighted magnetic resonance (MR) images (DCE-MRI) and 1H magnetic resonance
spectroscopy (MRS) for a precise biopsy for the detection of prostate cancer and for the delineation of intraprostatic
subvolumes for intensity modulated radiation therapy (IMRT).
Materials and Methods
Inclusion criteria: pathological prostate-specific antigen values (PSA) and/or previously negative transrectal
ultrasound guided biopsy. Standardised biopsy of the prostate divided into 20 regions. Image fusion of coloured
parametric maps derived from DCE-MRI and MRS (single voxel spectroscopy, SVS; chemical shift imaging, CSI)
with T2 images for morphological localisation using the MR-workstation, a separate CAD-workstation (CAD:
computer aided diagnosis) or radiation treatment planning system. Correlation of these intraprostatic subvolumes
with histology and cytokeratin-positive areas in prostatectomy species.
Results
DCE-MRI: Sensitivity 82%, specificity 89%, accuracy 88%, positive predictive value 61%, negative predictive value
96%. SVS: Sensitivity 55%, specificity 62%. CSI: Sensitivity 68%, specificity 67%. False positive findings due to
prostatitis, adenomatous hyperplasia, false negative findings due to low signal PIN (prostatic intraepithelial
neoplasis), cut-ff level for DCE-MRI: lesions smaller 3mm and less than 30% cancer cells, for SVS: lesions smaller
8 mm and less than 50% cancer cells, for CSI: lesions smaller 4 mm and less than 40% cancer cells. Our MR data
are correlated with published choline PET/CT data (PET/CT: hybrid scanner of positron emission tomography and
computed tomography).
Conclusions
DCE-MRI and MRS are helpful for a precise biopsy of the prostate. The European Society for Therapeutic Radiology
and Oncology (ESTRO) guidelines for 2006 for radiation treatment planning of the prostate have to be revised, if the
standardised biopsy will be replaced by a lesion-oriented biopsy. Until now it is unclear, if the parametric maps of
DCE-MRI and MRS can be used for radiation treatment planning of the prostate.
Schmuecking, Michael, et.al. Dynamic MRI and CAD vs. Choline MRS: Where is the detection level for a lesion characterisation in prostate
cancer? International Journal of Radiation Biology: 85:9, September 2008, 814-824.
20
Prostate Cancer Detection and Localization
Prostate Cancer Localization with DynamicContrast Enhanced MR Imaging and Proton MR
Spectroscopic Imaging*
Jurgen J. Fütterer, MD, Stijn W.T.P.J. Heijmink, MD, Tom W.J. Scheenen, Jeroen Veltman, MD,
Henkjan J. Huisman, Pieter Vos, Christina A. Hulsbergen-Van de Kaa, MD, J. Alfred Witjes, MD, Paul
F.M. Krabbe, Arend Heerschap, Jelle O. Barentsz, MD
Purpose
To prospectively determine the accuracies of T2-weighted magnetic resonance (MR) imaging, dynamic contrast
material-enhanced MR imaging, and quantitative three-dimensional (3D) proton MR spectroscopic imaging of the
entire prostate for prostate cancer localization, with whole-mount histopathologic section findings as the reference
standard.
Materials and Methods
This study was approved by the institutional review board, and informed consent was obtained from all patients.
Thirty-four consecutive men with a mean age of 60 years and a mean prostate-specific antigen level of 8 ng/mL
were examined. The median biopsy Gleason score was 6. T2-weighted MR imaging, dynamic contrast-enhanced
MR imaging, and 3D MR spectroscopic imaging were performed, and on the basis of the image data, two readers
with different levels of experience recorded the location of the suspicious peripheral zone and central gland
tumor nodules on each of 14 standardized regions of interest (ROIs) in the prostate. The degree of diagnostic
confidence for each ROI was recorded on a five-point scale. Localization accuracy and ROI-based receiver
oerating characteristic (ROC) curves were calculated.
Results
For both readers, areas under the ROC curve for T2-weighted MR, dynamic contrast-enhanced MR, and 3D MR
spectroscopic imaging were 0.68, 0.91, and 0.80, respectively. Reader accuracy in tumor localization with dynamic
contrast-enhanced imaging was significantly better than that with quantitative spectroscopic imaging (P .01).
Reader accuracy in tumor localization with both dynamic contrast-enhanced imaging and spectroscopic imaging
was significantly better than that with T2-weighted imaging (P .01).
Conclusion
Compared with use of T2-weighted MR imaging, use of dynamic contrast-enhanced MR imaging and 3D MR
spectroscopic imaging facilitated significantly improved accuracy in prostate cancer localization.
Futterer, Jurgen J., et.al. Prostate Cancer Localization with Dynamic Contrast-enhanced MR Imaging and Proton MR Spectroscopic Imaging.
Radiology: 241:2, November 2006, 449-458.
21
Prostate Cancer Staging
and Treatment Planning
Studies
Prostate Cancer Staging and Treatment Planning
Visualization of Prostate Cancer Using Dynamic
Contrast Enhanced MRI: Comparison With
Transrectal Power Doppler Ultrasound
H. Ito, MD, K. Kamoi, MD, PhD, K. Yokoyama, MD, PhD, K. Yamada, MD, PhD, and T. Nishamura, MD, PhD
This study was designed to assess the efficacy of dynamic contrast-enhanced MRI (DCE-MRI), in comparison
with power Doppler ultrasound (PDUS), for visualizing prostate cancer. 111 men suspected of having prostate
cancer underwent imaging before undergoing octant biopsy. Subsequently, 31 cancer-positive patients were
enrolled in this study. DCE-MRI was obtained using a three-dimensional fast-field echo sequence, which assured
wide coverage of the prostate gland. The transrectal PDUS were scored according to the degree of power Doppler
flow signals. The time intensity curve types for the DCE-MRI and the PDUS scores were compared with the
histopathologic results for each region. The time intensity curves were correlated significantly with PDUS scores
(p,0.001). Using PDUS, the overall sensitivity, specificity and accuracy of cancer visualization in peripheral zones
were 69%, 61% and 66%, respectively. Using DCE-MRI, the corresponding values were 87%, 74% and 82%. In the
inner gland, using PDUS, the overall sensitivity, specificity and accuracy were 68%, 94% and 83%, respectively.
Using DCE-MRI, the corresponding values were similar (68%, 86% and 78%). DCE-MRI was significantly more
sensitive than transrectal PDUS in peripheral zones (p,0.05). In conclusion, both transrectal PDUS and DCEMRI can be used to demonstrate hypervascularity in many prostate cancers. DCE-MRI was significantly more
sensitive than PDUS for visualizing of prostate cancers without loss of specificity in the peripheral zone.
Ito, H., et.al. Visualization of Prostate Cancer Using Dynamic Contrast-Enhanced MRI: Comparison With Transrectal Power Doppler Ultrasound. The British Journal of Urology: 76, 2003, 617-624.
23
Prostate Cancer Staging and Treatment Planning
Use of Dynamic Gadolinium-Enhanced Perfusion
MRI of Prostate Cancer to Assess Response to
CyberKnife Radiosurgery*
Russell N. Low, MD, Donald Fuller, MD, Naira Muradyan, PhD
Purpose
To evaluate the utility of dynamic gadolinium-enhanced perfusion MRI for preoperative planning and to monitor
response to CyberKnife® radiosurgery in patients with prostate cancer.
Materials and Methods
Fifty-four patients with proven prostate cancer treated with CyberKnife radiosurgery using the virtual HDR®
peripheral zone dose-escalation method underwent pre-CyberKnife MRI. MRI included thin section high resolution
T2-weighted imaging, dynamic gadolinium-enhanced perfusion MRI, and delayed high resolution SGE gadoliniumenhanced imaging. Prostate volume was calculated. iCAD’s workstation was used to generate color permeability
maps showing perfusion of the prostate gland and enhancing tumors. For identified tumors, permeability values
were calculated. Follow-up MRI has been performed at 2 months for 25 patients, 6 months for 29 patients, and 12
months for 9 patients. Repeated measurements of prostate volume and permeability values of visualized prostate
tumors have been performed. The percent change in these parameters was calculated for each patient at 2, 6, and
12 months. MRI findings were correlated with serial serum PSA values.
Results
The perfusion MRI depicted focal enhancing tumors in the prostate gland which correlated with biopsy results in
49 (.91) patients. In five patients focal lesions were not identified on the perfusion images. For the 49 patients with
focal lesions the pre-CyberKnife mean permeability of the tumor on the perfusion MRI was 2.04 min-1. Followup MRI demonstrated resolution of tumors on the perfusion images with decrease in the size and degree of
enhancement. For the entire studied population the mean tumor permeability value decreased to 1.14 at 2 months,
0.37 at 6 months, and 0.13 at 12 months. Evaluating sequential changes in individual patients, we observed a 36%
mean decrease in tumor permeability values at 2 months, 75% at 6 months, and 81% at 12 months. There are
several examples of virtually ablated perfusion in the peripheral zone, spatially coinciding with the 125%-150%
isodose line, manifest by 12 months post-treatment. The volume of the prostate gland showed a corresponding
decrease following CyberKnife radiotherapy with a 29% decrease at 2 months, 29% decrease at 6 months, and 37%
decrease at 12 months. At 12 months after CyberKnife radiosurgery prostate glands have shown decrease in gland
size, resolution of tumor enhancement, and marked decrease in overall enhancement of the prostate gland.
Corresponding mean PSA values in this cohort measured 8.46 ng/mL pre-treatment, 2.86 ng/mL 2 months posttreatment, 1.59 ng/mL 6 months post-treatment, and 1.44 ng/mL 12 months post-treatment. (con’t on page 25)
24
20
Prostate Cancer Staging and Treatment Planning
Use of Dynamic Gadolinium-Enhanced Perfusion
MRI of Prostate Cancer to Assess Response to
CyberKnife Radiosurgery
(con’t from page 25)
Conclusions
Dynamic gadolinium-enhanced perfusion MR imaging is a useful tool to monitor response of prostate cancer to
CyberKnife radiosurgery providing both qualitative and quantitative data. Routinely, by 12 months after CyberKnife
radiosurgery, prostate glands have shown a decrease in gland size, resolution of tumor enhancement, and marked
decrease in overall enhancement of the prostate gland, particularly within the peripheral zone, where some cases
demonstrate essentially zero perfusion.
Low, Russell, et.al., Use of Dynamic Gadolinium-Enhanced Perfusion MRI of Prostate Cancer to Assess Response to CyberKnife Radiosurgery.
Presented at CyberKnife User’s Meeting, February 9, 2009.
25
Prostate Cancer Staging and Treatment Planning
Accurate Determination of Extracapsular Extension
with High-Spatial-Resolution Dynamic ContrastEnhanced and T2-Weighted MR Imaging—Initial
Results*
B. Nicolas Bloch, MD, Edna Furman-Haran, PhD, Thomas H. Helbich, MD, Robert E. Lenkinski, PhD,
Hadassa Degani, PhD, Christian Kratzik, MD, Martin Susani, MD, Andrea Haitel, MD, Silvia Jaromi,
MD, Long Ngo, PhD, Neil M. Rofsky, MD
Purpose
To prospectively compare the sensitivity and specificity of high-spatial-resolution dynamic contrast material–
enhanced magnetic resonance (MR) imaging with those of high-spatial-resolution T2-weighted MR imaging,
performed with an endorectal coil (ERC), for assessment of extracapsular extension (ECE) and staging in patients
with prostate cancer, with histopathologic findings as reference.
Materials and Methods
The study was approved by the institutional internal review board; a signed informed consent was obtained. MR
imaging of the prostate at 1.5 T was performed with combined surface coils and ERCs in 32 patients (mean age,
65 years; range, 42–78 years) before radical prostatectomy. High-spatial-resolution T2-weighted fast spin-echo
and high-spatial-resolution dynamic contrast-enhanced three-dimensional gradient-echo images were acquired
with gadopentetate dimeglumine. Dynamic contrast-enhanced MR images were analyzed with a computergenerated color-coded scheme. Two experienced readers independently assessed ECE and tumor stage. MR
imaging–based staging results were compared with histopathologic results. For the prediction of ECE, sensitivity,
specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. Staging accuracy
was determined with the area under the receiver operating characteristic curve (AUC) by using the Wilcoxon-MannWhitney index of diagnostic accuracy.
Results
The mean sensitivity, specificity, PPV, and NPV for assessment of ECE with the combined data sets for both readers
were 86%, 95%, 90%, and 93%, respectively. The sensitivity of MR images for determination of ECE was significantly
improved for both readers (25%) with combined data sets compared with T2-weighted MR images alone. The
combined data sets had a mean overall staging accuracy for both readers of 95%, as determined with AUC. Staging
results for both readers were significantly improved (P<.05) with the combined data sets compared with T2weighted MR images alone.
(con’t on page 27)
26
Prostate Cancer Staging and Treatment Planning
Accurate Determination of Extracapsular Extension
with High-Spatial-Resolution Dynamic ContrastEnhanced and T2-Weighted MR Imaging—Initial
Results*
(con’t from page 26)
Conclusions
The combination of high-spatial-resolution dynamic contrast-enhanced MR imaging and T2-weighted MR imaging
yields improved assessment of ECE and better results for prostate cancer staging compared with either technique
independently.
Bloch, B. Nicolas, et.al. Accurate Determination of Extracapsular Extension with High-Spatial-Resolution Dynamic Contrast-enhanced and
T2-weighted MR Imaging—Initial Results. Radiology: 245, October 2007, 176-185.
27
Prostate Cancer Staging and Treatment Planning
MRI and Prostatic Cancer: Measurements of
Kinetic Perfusion Parameters of Gadolinium with a
Computerized-Aided Detection Tool (CAD)
J.-L. Sauvain, P. Palascak, W. Gomez, N. Nader, J.-M. Bremon, P. Bloqueau, L. Jung, P. Maniere,
R. Papavero, P. Rhomer
Objectives
To assess with a CAD in the peripheral (ZP) and transitional (ZT) zones the areas with modifications of the kinetic
parameter Kep (ratio of exchanges between vascular compartment and extravascular extracellular spaces) in
prostatic cancers with DCE MRI before radical prostatectomy.
Methods
Forty-two consecutive patients (mean age 67 years, mean PSA: 8.9 ng/ml) with a prostatic cancer proved after
a set of 12 biopsies underwent, before radical prostatectomy, a dynamic MRI (1.5T) with a surface coil after
injection of gadolinium. We look with a CAD for foci of voxels with an abnormal Kep in ZP and/or in ZT. Foci of
abnormal voxels computerized were compared with histological results of radical prostatectomies: prostates
were shared in 12 sectors (six peripheral and six central) and a total of 504 sectors were studied. The links
between prostatic capsule and foci of voxels with elevated Kep were systematically evaluated. The location and
the local extension of the various cancerous foci were estimated. A comparison with the results of T2W and T1
DCE MRI sequences without the use of CAD was made.
Results
Eighty-eight percent of investigated patients revealed at least a cancerous focus associated with a group of
pathological voxels. Hundred and seventy-eight of the 504 investigated prostatic sectors revealed a cancerous
lesion after radical prostatectomy (RP) and 116 a focus of voxels with a pathological Kep being linked to 71
isolated lesions, some of them filling several sectors (47 peripheral and 24 transitional). The automatic research
with the software of foci of voxels with a parameter Kep more than 2,2 per minute to detect a cancerous lesion
had a sensitivity by sector less than the reading without CAD (69% in ZP and 58% in ZT against respectively, 85
and 66% (p<0.01) but seemed more specific: 98% in ZP and 95% in ZT against respectively, 80 and 82% (p<0.01).
After RP, 16 cancers were classified Pt2, 10Pt2$+ and 15 Pt3. The CAD had a better accuracy (74%) that T2W MRI
(60%) to look for an extracapsular extension (EPE) or a rist of positive margins: 86% of extraprostatic extension
and 60% of positive margins were near a focus of pathological voxels.
(con’t on page 29)
28
Prostate Cancer Staging and Treatment Planning
MRI and Prostatic Cancer: Measurements of
Kinetic Perfusion Parameters of Gadolinium with a
Computerized-Aided Detection Tool (CAD)
(con’t from page 28)
Conclusions
CAD allowed a computerized qualitative and quantitative study of DCE MRI. It identified and localized with a good
specificity the significant foci. A focus of voxels with elevated Kep against the capsule increased significantly the risk
of an extraprostatic extension or a positive margin after radical prostatectomy.
Sauvain, J-L., et.al. MRI and prostatic cancer: Measurements of kinetic perfusion parameters of gadolinium with a computerized-aided
diagnostic tool (CAD). Prog. Urol.: 2009, doi: 10.1016.
29
Prostate Cancer Staging and Treatment Planning
Gadolinium-Enhanced MRI in the Evaluation of
Minimally Invasive Treatments of the Prostate:
Correlation with Histopathologic Findings
Benjamin T. Larson, Joseph M. Collins, Christian Huidobro, Alberto Corica, Santiago Vallejo, David
G. Bostwick
Objectives
To explore the use of magnetic resonance imaging (MRI) with gadolinium enhancement as a noninvasive method to
image the extent of ablation after minimally invasive treatment. Minimally invasive methods for ablating prostatic
tissue have emerged as a viable option in the treatment of prostate disease. As these devices enter the mainstream
of patient care, imaging methods that verify the exact location, extent, and pattern of ablation are needed.
Methods
Nineteen patients with prostate cancer were evaluated. All received some type of minimally invasive treatment,
post-treatment gadolinium-enhanced MRI sequences, and radical retropubic prostatectomy for histopathologic
evaluation. Visual comparisons of gadolinium defects and areas of coagulation necrosis as seen on histopathologic
evaluation were made by us. Volumetric and two-dimensional area measurements of the ablation lesions were also
compared for correlation between the MRI and histopathologic results.
Results
Gadolinium-enhanced MRI could be matched to histopathologic findings by visual comparison in 17 of the 19 cases.
Surgically distorted histopathological specimens and a small periurethral lesion caused 2 patients to have MRI and
histopathological results that could not be matched. Complete volumetric measurements were available for 16
of the 19 patients and correlated strongly (r = 0.924). The two-dimensional area data for all patients also showed
significant correlation (r = 0.886).
Conclusions
Correlation with histopathologic findings showed gadolinium-enhanced MRI to be useful for determining the
location, pattern, and extent of necrosis caused within the prostate by minimally invasive techniques. Gadoliniumenhanced MRI gives the urologist a useful tool to evaluate the effectiveness of new minimally invasive therapies.
Larson, Benjamin T., et.al. Gadolinium-Enhanced MRI in the Evaluation of Minimally Invasive Treatments of the Prostate: Correlation with
Histopathological Findings. Urology: 62, 2003, 900-904.
30
Prostate Cancer Staging and Treatment Planning
Dynamic Contrast Enhanced MRI of Prostate
Cancer: Correlation with Morphology and Tumour
Stage, Histological Grade and PSA*
Anwar R. Padhani, Connie J. Gapinski, David A. Macvicar, Geoffrey J. Parker, John Suckling, Patrick
B. Revell, Martin O. Leach, David P. Dearnaley, Janet E. Husband
Aim
To quantify MRI enhancement characteristics of normal and abnormal prostatic tissues and to correlate these with
tumour stage, histological grade and tumour markers.
Materials and Methods
Quantitative gradient recalled echo MR images were obtained following bolus injection of gadopentetate
dimeglumine in 48 patients with prostate cancer. Turbo spin-echo T2-weighted images at the same anatomical
position were reviewed for the presence of tumours (45 regions), normal peripheral zone (33 regions), and normal
appearing central gland (30 regions). Time-signal intensity parameters (onset time, mean gradient and maximal
amplitude of enhancement and wash-out score) and modeling parameters (permeability surface area product,
lesion leakage space and maximum gadolinium concentration) were correlated with tumour stage, histological
grade (Gleason score) and serum prostatic specific antigen (PSA) levels.
Results
Significant differences were noted between peripheral zone and tumour with respect to signal intensity
and modeling parameters (P=0.0001), except onset time. No differences between central gland and tumour
enhancement values were seen. There was weak correlation between MRI tumour stage and tumour vascular
permeability (r2 = 12%; P=0.02) and maximum tumour gadolinium concentration (r2=14%; P=0.015). However, no
significant correlations were seen with Gleason score or PSA levels.
Conclusion
Quantification of MR contrast enhancement characteristics allows tissue discrimination in prostate cancer
consistent with known variations in microvessel density estimates.
Padhani, Anwar, et.al. Dynamic Constrast Enhanced MRI of Prostate Cancer: Correlation with Morphology and Tumour Stage, Histological
Grade and PSA. Clinical Radiology: 55, 2000, 99-109.
31
Prostate Cancer Staging and Treatment Planning
Prostate MRI and Surgical Planning in RoboticAssisted Laparoscopic Prostatectomy
T. McClure, D. Margolis, A. Thomas, S. Raman, R. Reiter
Objective
Conventional nerve sparing radical prostatectomy relies on haptic feedback in the assessment of the neurovascular
bundle (NVB). NVB preservation improves postoperative rates of both continence and potency. Robotic-assisted
laparoscopic prostatectomy (RALP) touts improved visualization of the NVB but at a cost of loss of haptic feedback,
which may lead to increased rates of positive surgical margins. Prostate MR has previously demonstrated its
efficacy in the staging of prostate cancer. Therefore, it may give the robotic surgeon additional information to
compensate for this loss of haptic feedback. We investigate the utility of endorectal MR of the prostate in changing
surgical the decision making with regards to nerve sparing RALP.
Materials and Methods
After Institutional Review Board approval, the charts of 104 men with biopsy-proved prostate cancer who underwent
preoperative endorectal prostate MR prior to RALP were evaluated. 1.5T MRI included T2WI, diffusion-weighted
imaging, dynamic contrast enhanced imaging, and MR spectroscopy. A single surgeon then determined the
preoperative plan: initially on clinical information and then on clinical information and the final MR report. Any
changes in the surgical plan with regards to NVB preservation and actual surgical technique were noted.
Results
Twenty nine of 104 patients had the nerve sparing technique changed because of MRI. Of patients for whom the
plan was changed, 17 of 29 (49%) underwent nerve sparing surgery and 12 of 29 (40%) patients had their plan
changed to nonnerve sparing surgery. The rate of positive margins was 6.7% (7/104 patients). Six of 7 (87%) patients
with positive margins were seen in patients with MR images that made no change in the operative plan. One of
seven patients (14%) had a positive margin in which the MRI changed operative plan to nerve sparing surgery In
patients that had their surgical plan changed to nonnerve sparing techniques zero had positive margins.
Conclusion
RALP is limited by a lack of haptic feedback, a component urologic surgeons use to evaluate the NVBs and determine if a nerve sparing technique is possible. Preoperative prostate MRI helps the robotic surgeon compensate for
this lack of tactile feedback to optimize nerve sparing technique without compromising oncological outcome. MRI of
the prostate may help the urologic surgeon with operative planning by optimizing NVB sparing without compromising oncologic outcome.
McClure, Timothy, et.al. Prostate MRI and Surgical Planning in Robotic-Assisted Laparoscopic Prostatectomy. Presented at the 110th Annual Meeting of the American Roentgen Ray Society: May, 2010.
32
Prostate Imaging
Treatment Monitoring
Studies
Prostate Cancer Treatment Monitoring
CyberKnife Radiotherapy of Osseous Tumors: Use
of Dynamic Gadolinium-Enhanced Perfusion MR
Imaging for Planning and Monitoring Response to
Therapy*
Russell N. Low, MD, Donald Fuller, MD, Neeraj Panchal, MD
Purpose
To describe our preliminary experience using dynamic contrast enhanced MRI for treatment planning and to
monitor response of osseous tumors to CyberKnife® stereotactic radiotherapy.
Method and Materials
Ten patients with tumors of osseous structures including pelvis (4), spine (4), and skull base (3) were referred for MRI
prior to robotic CyberKnife radiotherapy. MRI included T1, fat surpressed T2, dynamic gadolinium-enhanced perfusion
imaging, and delayed fat surpressed 2D and 3D SPGR imaging. To date six patients have been evaluated with repeat
MR imaging 1-6 months after CyberKnife treatment. The dynamic contrast enhanced (DCE) perfusion MR imaging was
performed with a temporal resolution of 10-19 seconds using a 3D FSPGR sequence (TR 2-3 msec, TE min, 160x160,
3-5 mm thickness, 2 NEX). MR imaging was started 20 seconds after the injection of 0.1 mmol/kg gadolinium chelate
and was continued for 7 min. DCE data set was processed on a CAD Sciences (iCAD) workstation with calculation of
tumor permeability values, tumor extracellular volumes, and generation of colorized permeability maps.
The pre and post CyberKnife anatomic imaging were separately evaluated by two observers without the DCE
to determine response to therapy. Tumor size, location, and degree of delayed enhancement were noted. The
DCE imaging was then evaluated for changes in the quantitative tumor permeability value and in the colorized
permeability map.
Results
In the six patients with follow up MR examinations review of anatomic MR images showed no change in tumor size,
location, or degree of delayed enhancement in all 6 patients. On the DCE images the pre-treatment mean 50% and
90% permeability values were 4.78 and 11.85 compared to 1.06 and 1.95 on the post-treatment DCE MRI. On the DCE
all six patients demonstrated a decrease in tumor perfusion with an average 79% decrease in the 50% permeability
value and 75% decrease in 90% permeability value of the tumor. Interval decrease in tumor perfusion was evident on
the colorized permeability maps with decrease of resolution of the highly vascular areas within the tumors.
Conclusion
Dynamic gadolinium-enhanced perfusion MR imaging is an effective means to evaluate osseous tumors before and
following CyberKnife radiotherapy.
Low, Russell, et.al., Radiotherapy of Osseous Tumors: Use of Dynamic Gadolinium-Enhanced Perfusion MR Imaging for Planning and
Monitoring Response to Therapy. Presented at RSNA, November 30, 2008.
34
Prostate Cancer Treatment Monitoring
Endorectal and Dynamic Contrast-Enhanced MRI
for Detection of Local Recurrence After Radical
Prostatectomy*
Emanuele Casciani, Elisabetta Polettini, Enrico Carmenini, Irene Floriani, Gabriele Masselli, Luca
Bertini, Gian Franco Gualdi
Objective
The objective of our study was to evaluate the sensitivity and specificity of endorectal MRI combined with dynamic
contrast-enhanced MRI to detect local recurrence after radical prostatectomy.
Materials and Methods
A total of 51 patients who had undergone radical prostatectomy for prostatic adenocarcinoma 10 months to 6
years before underwent a combined endorectal coil MRI and dynamic gadolinium-enhanced MRI before endorectal
sonographically guided biopsy of the prostatic fossa. The MRI combined with MR dynamic imaging results were
correlated with the presence of recurrence defined as a positive biopsy result or reduction in prostate-specific
antigen level after radiation therapy. The pre and post CyberKnife anatomic imaging were separately evaluated
by two observers without the DCE to determine response to therapy. Tumor size, location, and degree of
delayed enhancement were noted. The DCE imaging was then evaluated for changes in the quantitative tumor
permeability value and in the colorized permeability map.
Results
Overall data of 46 (25 recurred, 21 nonrecurred) out of 51 evaluated patients were analyzed. All recurrences showed
signal enhancement after gadolinium administration and, in particular, 22 of 24 patients (91%) showed rapid and
early signal enhancement. The overall sensitivity and specificity of MR dynamic imaging was higher compared
with MRI alone (88%, [95% CI] 69–98% and 100%, 84–100% compared with 48%, 28–69% and 52%, 30–74%). MRI
combined with dynamic imaging allowed better identification of recurrences compared with MRI alone (McNemar
test: chi-square1 = 16.67; p = < 0.0001).
Conclusion
MRI combined with dynamic contrast-enhanced MRI showed a higher sensitivity and specificity compared with MRI
alone in detecting local recurrences after radical prostatectomy.
Casciani, Emanuele, et.al., Endorectal and Dynamic Constrast-Enhanced MRI for Detection of Local Recurrence After Radical Prostatectomy.
AJR: 190, May 2008, 1187-1192.
35
Prostate Cancer Treatment Monitoring
MRI Techniques for Prediction of Local Tumor
Progression After High-Intensity Focused
Ultrasonic Ablation of Prostate Cancer
Chan Kyo Kim, Byung Kwan Park, Hyun Moo Lee, Sam Soo Kim, EunJu Kim
Objective
The purpose of this study was to evaluate the diagnostic performance of dynamic contrast-enhanced MRI (DCEMRI) and of T2-weighted MRI with diffusion weighted imaging (DWI) for predicting local tumor progression after
high-intensity focused ultrasonic ablation of localized prostate cancer.
Methods and Materials
Twenty-seven patients who had increased levels of prostate-specific antigen after high-intensity focused ultrasonic
ablation underwent MRI and endorectal biopsy. The MR images and biopsy results were correlated for six prostate
sectors. Residual or recurrent prostate cancer after treatment was defined as local tumor progression if the biopsy
results showed cancer foci. Two readers blinded to the clinical findings and biopsy results used a 5-point scale
to independently assess DCE-MR images and T2-weighted and diffusion-weighted MR images. The results were
compared by use of the McNemar test with Bonferroni correction, generalized estimating equations, and receiver
operating characteristic analysis.
Results
After high-intensity focused ultrasonic ablation, local tumor progression was pathologically detected in 54 (33%)
of 162 sectors in 18 patients. The sensitivities of DCE-MRI and T2-weighted MRI with DWI were 80% and 63% for
reader 1 (p = 0.004) and 87% and 70% for reader 2 (p = 0.004). The specificities of DCE-MRI and T2-weighted MRI
with DWI were 68% and 78% for reader 1 (p = 0.002) and 63% and 74% for reader 2 (p < 0.001). The accuracy rates
of DCE-MRI and T2-weighted MRI with DWI were 72% and 73% for reader 1 (p > 0.05) and 71% and 73% for reader 2
(p > 0.05). The areas under the receiver operating characteristic curve for DCE-MRI and T2-weighted MRI with DWI
were 0.77 and 0.77 for reader 1 and 0.85 and 0.81 for reader 2.
Conclusion
For prediction of local tumor progression of prostate cancer after high-intensity focused ultrasonic ablation, DCEMRI was more sensitive than T2-weighted MRI with DWI, but T2-weighted MRI with DWI was more specific than
DCE-MRI.
Kim, Chan Kyo., et.al. MRI Techniques for Prediction of Local Tumor Progression After High-Intensity Focused Ultrasonic Ablation of Prostate
Cancer. AJR: 190, 2008, 1180-1186.
36
Prostate Cancer Treatment Monitoring
Dynamic Contrast-Enhanced Magnetic Resonance
Imaging for Localization of Recurrent Prostate
Cancer After External Beam Radiotherapy
Masoom A. Haider, MD, Peter Chung, MD, Joan Sweet, MD, Ants Toi, MD, Kartik Jhaveri, MD, Cynthia
Ménard, MD, Padraig Warde, MD, John Trachtenberg, MD, Gina Lockwood, M. Math., Michael
Milosevic, MD
Purpose
To compare the performance of T2-weighted (T2w) imaging and dynamic contrast-enhanced (DCE) magnetic
resonance imaging (MRI) of the prostate gland in the localization of recurrent prostate cancer in patients with
biochemical failure after external beam radiotherapy (EBRT).
Methods and Materials
T2-weighted imaging and DCE MRI were performed in 33 patients with suspected relapse after EBRT. Dynamic
contrast-enhanced MRI was performed with a temporal resolution of 95 s. Voxels enhancing at 46 s after injection
to a greater degree than the mean signal intensity of the prostate at 618 s were considered malignant. Results
from MRI were correlated with biopsies from six regions in the peripheral zone (PZ) (base, mid, and apex). The
percentage of biopsy core positive for malignancy from each region was correlated with the maximum diameter of
the tumor on DCE MRI with a linear regression model.
Results
On a sextant basis, DCE MRI had significantly better sensitivity (72% [21 of 29] vs. 38% [11 of 29]), positive predictive
value (46% [21 of 46] vs. 24% [11 of 45]) and negative predictive value (95% [144 of 152] vs. 88% [135 of 153] than
T2w imaging. Specificities were high for both DCE MRI and T2w imaging (85% [144 of 169] vs. 80% [135 of 169]).
There was a linear relationship between tumor diameters on DCE MRI and the percentage of cancer tissue in the
corresponding biopsy core (r = 0.9, p < 0.001), with a slope of 1.2.
Conclusions
Dynamic contrast-enhanced MRI performs better than T2w imaging in the detection and localization of prostate
cancer in the peripheral zone after EBRT. This may be helpful in the planning of salvage therapy.
Haider, Masoom A., et.al. Dynamic Constrast-Enhanced Magnetic Resonance Imaging For Localization of Recurrent Prostate Cancer After
External Beam Radiotherapy. Int.J. Radiation Oncology Biol. Phys.: 70, 2008, 425-430.
37
Prostate Cancer Treatment Monitoring
Recurrent Prostate Cancer After External Beam
Radiotherapy: Value of Contrast-Enhanced Dynamic
MRI in Localizing Intraprostatic Tumor — Correlation
with Biopsy Findings
Olivier Rouvière, Olivier Valette, Stéphanie Grivolat, Catherine Colin-Pangaud, Raymonde Bouvier,
Jean Yves Chapelon, Albert Gelet, Denis Lyonnet
Objectives
To assess the accuracy and interobserver variability of T2-weighted (T2W) and contrast-enhanced dynamic (CEDyn) magnetic resonance imaging (MRI) in predicting the results of transrectal biopsy in patients with suspected
recurrent prostate cancer after external beam radiotherapy.
Methods
A total of 22 patients with increasing prostate-specific antigen levels after external beam radiotherapy for prostate
cancer underwent T2W and CE-Dyn MRI of the prostate. The CE-Dyn sequence (acquisition time 30 seconds) was
repeated three times after the injection of gadolinium. All patients underwent subsequent transrectal biopsy. Three
independent readers interpreted the MRI scans. The MRI and biopsy results were correlated in 10 prostate sectors
(the sextants of the peripheral zone, the two transitional zones, and the two seminal vesicles.)
Results
Biopsy cores were obtained in 147 prostate sectors. Of these, 63 were positive for cancer in 19 patients. On the T2W
images, the three readers interpreted as postitive for cancer 15, 15, and 13 of the 19 patients showing cancer at
biopsy. They interpreted as negative 3, 0, and 1 of the 3 patients showing no cancer at biopsy. On CE-Dyn images,
the three readers correctly classified all the patients as positive or negative for cancer. The T2W and CE-Dyn MRI
findings were concordant with biopsy results in, respectively, 81 to 95 and 107 to 117 prostate sectors (P<0.001 and
P<0.01 for readers 1 and 2 and was nonsignificant for reader 3.) The interobserver agreement was better for CE-Dyn
images (kappa = 0.63 to 0.70) than for the T2W images (kappa = 0.18 to 0.39). The MRI-calculated tumor volumes
and the mean biopsy core invasion rates were significantly correlated on the CE-Dyn images for all readers. They
correlated significantly on T2W images only for one reader.
Conclusions
CE-Dyn MRI depicts the intraprostatic distribution of recurrent cancer after external beam radiotherapy more
accurately and with less interobserver variability than T2W MRI.
Rouviere, Olivier, et.al. Recurrent Prostate Cancer After External Beam Radiotherapy: Value of Contrast-Enhanced Dynamic MRI in
Localizing Intraprostatic Tumor - Correlation with Biopsy Findings. Urology: 63, 2004, 922-927.
38
Supplemental Information
Supplemental Information: VividLook and
VersaVue Enterprise
Computer-Enhanced Prostate MR Analysis
Streamlines Workflow and Provides Robust
Information
VividLook®, iCAD’s MR Prostate analysis solution, provides more diagnostic information by utilizing all available
time points and creating colorized images based on signal changes defined by tumor physiology. All-Time Point
(ATP) analysis is combined with an advanced pharmacokinetic model that calculates numerical values of key
physiological parameters allowing the user to discern the different contrast enhancement profiles in malignant
versus benign tumors.
VersaVue™ Enterprise image review and analysis software provides
maximum functionality facilitating the analysis of ATP colorized images and
quantitative data. Using VersaVue, users can view contrast enhancement
curves, dynamic images and histograms of key lesion parameters.
VersaVue’s automation of critical manual steps results in a radical reduction
in the time required to generate ROI curves and a significant improvement
in streamlining the radiologist’s workflow and diagnosis. iCAD’s solution
also allows the user to create standard and customized reports with detailed
and comprehensive information critical to the identification and analysis
of abnormalities. Colorized images within the report assist clinicians to
effectively communicate options to referring physicians and their patients.
VividLook image clearly defines the
enhancing bilateral prostate cancers.
VividLook and VersaVue are specifically designed to improve the analysis
workflow, interventional planning, and reporting of prostate MR results.
Increased diagnostic confidence through an advanced post-processing algorithm powered by ATP
technology.
ATP analyzes ALL available time points in dynamic contrast enhanced MR
images of the prostate. The algorithm conducts a continuous analysis of the
entire data set versus an analysis of a few discrete time points. As a result,
the performance of ATP is independent of dynamic protocol changes and
of contrast injection timing. Because it uses all available time points, ATP
analyzes contrast enhancement from MRI datasets in a manner that is less
affected by noise or other external factors such as patient motion.
ATP uses the whole signal enhancement curve to perform pharmacokinetic
analysis on a voxel-by-voxel basis. The physiological parameters are
calculated and used for tissue differentiation and may aid in distinguishing
benign versus malignant lesions. Based on the value of those parameters,
voxels are colorized with a specific color hue and intensity that helps
distinguish tissue and lesions.
40
T2-weighted image shows ill-defined low
intensity lesions in the peripheral zone
bilaterally.
Supplemental Information: VividLook and
VersaVue Enterprise (con’t)
Thin client architecture provides faster data access and read anywhere capability.
VividLook’s thin client architecture is specifically designed to provide users with increased speed and greater
flexibility. The solution offers on demand viewing of studies which minimizes time to begin study interpretation.
No additional hardware is required at each reading location, allowing case review any time, anywhere.
In addition, VividLook and VersaVue provide the most powerful and flexible DICOM connectivity solutions –
enhancing workflow and enabling seamless integration with all leading acquisition systems, review workstations,
and PACS solutions. Flexible integration options can send and receive original and parametric images to and
from any DICOM viewer or PACS device in your network.
VividLook enhances imaging workflow and increases your diagnostic confidence while reducing
operating costs and increasing patient value.
Full PACS storage and retrieval capabilities
Calculates physiological parameters of lesions and generates histograms:
- Extracellular Volume Fraction
- Vascular Permeability
VersaVue image review and analysis software facilitates the analysis of ATP colorized images and
quantitative data.
Advanced hanging protocol configuration options
Integrated 3D/4D displays for rapid, efficient interpretation
- View dynamic contrast changes on any single slice on the fly
Colorized image overlays on any underlying MR sequence
One-click ROI
Customizable analysis and reporting tools
- Reports, images, charts can all be archived to PACS
- Lesion analysis summary for easier dictation
Time-intensity curve generated by VersaVue Enterprise review software.
41
Supplemental Information: Prostate Cancer
Resources
Websites
Admetech
http://www.admetech.org/
American Cancer Society
http://www.cancer.org/docroot/home/index.asp
Prostate Cancer Foundation
http://www.prostatecancerfoundation.org/
National Institutes of Health
http://www.cancer.gov/cancerinfo/types/prostate
National Cancer Institute
http://www.cancer.gov/cancertopics/wyntk/prostate
National Prostate Coalition
www.zerocancer.org/index.html
American Urological Association Foundation
www.urologyhealth.org
National Prostate Cancer Coalition
www.4npcc.org
Publications
Bard, Robert L. Dynamic Contrast-Enhanced MRI Atlas of Prostate Cancer. New York:
Springer, 2009.
42
Supplemental Information:
Glossary of Prostate Imaging Acronyms
ATP
All-Time Points
AUGC
Area under the gadolinium concentration curve
BPH
Benign prostatic hyperplasia
DCE or CE-Dyn
Dynamic contrast-enhanced
DRE
Digital rectal exam
DWI
Diffusion weighted imaging
EBRT
External beam radiotherapy
ECE
Extracapsular extension
EVF
Extracellular volume fraction
KEP
Contrast efflux rate constant (also known as permeability/EVF)
KTRANS
Contrast influx rate constant (also known as permeability from blood to lesion
tissue leakage space)
MRI
Magnetic resonance imaging
NPV
Negative predictive value
PACS
Picture archiving and communications system
PDUS
Power Doppler ultrasound
PPV
Positive predictive value
PSA
Prostate specific antigen
PZ
Peripheral zone
ROI
Region of Interest
T1W
T1 weighted imaging
T2W
T2 weighted imaging
TRUS
Transrectal ultrasound
TZ
Transitional zone
Ve
Fractional volume of extracellular space per unit volume of tissue (also known
as extracellular volume fraction)
43
About iCAD
iCAD, Inc. is an industry-leading provider of advanced image
analysis and workflow solutions that enable healthcare
professionals to better serve patients by identifying
pathologies and pinpointing cancer earlier. iCAD offers a
comprehensive range of high-performance, upgradeable
Computer-Aided Detection (CAD) systems and workflow
solutions for mammography (film-based, digital radiography
(DR) and computed radiography (CR)), Magnetic Resonance
Imaging (MRI), and Computed Tomography (CT).
Since receiving FDA approval for the Company’s first breast
cancer detection product in 2002, over 3,100 iCAD systems
have been placed in healthcare practices worldwide. iCAD’s
solutions aid in the early detection of the most prevalent
cancers including breast, prostate and in the future, colon
and lung cancer.
For more information, call (877) iCADnow or visit
www.icadmed.com.
44
®
98 Spit Brook Road, Suite 100 Nashua, NH 03062
+1 866 280 2239 toll free
+1 937 431 1464 phone
sales@icadmed.com email
www.icadmed.com